Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab Biosimilar in Psoriasis Vulgaris (Switch and Biologic-Naïve Study)
jRCTs041240172Active, not recruiting
- Sponsor
- Fuji Pharma Co., Ltd.
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of ustekinumab in plaque psoriasis and psoriatic arthritis (PsA) (2 arms), sponsored by Fuji Pharma Co., Ltd. Primary endpoint: Safety evaluation. Started Mar 2025; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCTs041240172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240172.